{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "https://eldaddp.azurewebsites.net/answeredquestions.text?date=2015-09-11&AnsweringBody.=Department+of+Health&writtenParliamentaryQuestionType=NamedDay", "definition" : "https://eldaddp.azurewebsites.net/meta/answeredquestions.text?date=2015-09-11&AnsweringBody.=Department+of+Health&writtenParliamentaryQuestionType=NamedDay", "extendedMetadataVersion" : "https://eldaddp.azurewebsites.net/answeredquestions.text?date=2015-09-11&AnsweringBody.=Department+of+Health&_metadata=all&writtenParliamentaryQuestionType=NamedDay", "first" : "https://eldaddp.azurewebsites.net/answeredquestions.text?date=2015-09-11&_page=0&AnsweringBody.=Department+of+Health&writtenParliamentaryQuestionType=NamedDay", "hasPart" : "https://eldaddp.azurewebsites.net/answeredquestions.text?date=2015-09-11&AnsweringBody.=Department+of+Health&writtenParliamentaryQuestionType=NamedDay", "isPartOf" : "https://eldaddp.azurewebsites.net/answeredquestions.text?date=2015-09-11&AnsweringBody.=Department+of+Health&writtenParliamentaryQuestionType=NamedDay", "items" : [{"_about" : "http://data.parliament.uk/resources/418451", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/418451/answer", "answerText" : {"_value" : "
No such assessment has been made. We remain committed to continuing to invest in the Cancer Drugs Fund which has so far benefitted over 72,000 people with cancer in England.<\/p>
<\/p>
<\/p>
<\/p>
We understand that NHS England continues to work with manufacturers seeking to maintain drug and indication combinations within the Fund.<\/p>
<\/p>
<\/strong><\/p> <\/p> NHS England has confirmed that patients who are already receiving a drug/indication which is to be removed from the Fund will continue to be treated with that drug until they and their clinicians consider it appropriate to discontinue treatment. In addition, drugs removed from the Fund will continue to be available via Individual Funding Requests if the individual patient meets clinical exceptionality criteria.<\/p> <\/p> <\/strong><\/p> <\/p> <\/strong><\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
, "dateOfAnswer" : {"_value" : "2015-09-16", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2015-09-16T15:22:40.517Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2015-09-11", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Cancer Drugs Fund"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, what assessment he has made of the implications for his policies of the decision by NHS England announced on 4 September 2015 to remove (a) the pancreatic cancer drug Abraxane and (b) 22 other drugs and indications from the Cancer Drugs Fund list of approved drugs.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4056", "label" : {"_value" : "Biography information for Nic Dakin"}
}
, "tablingMemberConstituency" : {"_value" : "Scunthorpe"}
, "tablingMemberPrinted" : [{"_value" : "Nic Dakin"}
], "uin" : "10091"}
, {"_about" : "http://data.parliament.uk/resources/418452", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/418452/answer", "answerText" : {"_value" : " NHS England has advised that the mechanisms for appeal are as set out in Appendix G, section 11 of the Cancer Drugs Fund Standard Operating Procedures which are published on NHS England\u2019s website at:<\/p> <\/p> <\/p> <\/p> www.england.nhs.uk/wp-content/uploads/2013/04/cdf-sop-2015-16.pdf<\/a><\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
, "dateOfAnswer" : {"_value" : "2015-09-16", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2015-09-16T15:23:43.363Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2015-09-11", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Cancer Drugs Fund"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, what mechanisms there are for appeal against NHS England's decision announced on 4 September 2015 to remove (a) Abraxane and (b) 22 other drugs and indications from the Cancer Drugs Fund list of approved drugs; and if he will make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4056", "label" : {"_value" : "Biography information for Nic Dakin"}
}
, "tablingMemberConstituency" : {"_value" : "Scunthorpe"}
, "tablingMemberPrinted" : [{"_value" : "Nic Dakin"}
], "uin" : "10092"}
, {"_about" : "http://data.parliament.uk/resources/418453", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/418453/answer", "answerText" : {"_value" : " Neither the Department nor NHS England has made any such assessment.<\/p> <\/p> <\/p> <\/p> Advances in medical science means that new cancer medicines are emerging all the time and NHS England needs to regularly prioritise its national Cancer Drugs Fund (CDF) list so people can access these too. Decisions on which treatments are included on the list are made by the CDF expert clinical panel because it is right these decisions are clinically led.<\/p> <\/p> <\/p> <\/p> <\/p> <\/p> <\/strong><\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
, "dateOfAnswer" : {"_value" : "2015-09-16", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2015-09-16T15:25:30.407Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2015-09-11", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Cancer Drugs Fund"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, what assessment he has made of the effect on cancer clinical trials of NHS England's decision announced on 4 September 2015 to remove (a) Abraxane and (b) 22 other drugs and indications from the Cancer Drugs Fund list of approved drugs; and if he will make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4056", "label" : {"_value" : "Biography information for Nic Dakin"}
}
, "tablingMemberConstituency" : {"_value" : "Scunthorpe"}
, "tablingMemberPrinted" : [{"_value" : "Nic Dakin"}
], "uin" : "10093"}
, {"_about" : "http://data.parliament.uk/resources/418455", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/418455/answer", "answerText" : {"_value" : " The ProtecT randomised controlled trial is evaluating the effectiveness, cost-effectiveness and acceptability of active monitoring, radical 3D conformal radiotherapy and radical prostatectomy in men with clinically localised prostate cancer, identified through population-based PSA (Prostate Specific Antigen) testing.<\/p> <\/p> <\/p> <\/p> There have already been over 100 published outputs from ProtecT and these are listed on the National Institute for Health Research (NIHR) website:<\/p> <\/p> <\/p> <\/p> www.nets.nihr.ac.uk/projects/hta/962099<\/p> <\/p> <\/p> <\/p> The researchers plan to publish the primary and most secondary analyses during 2016 at major relevant conferences and in peer-reviewed journals. The primary outcome to be evaluated is definite or probable prostate cancer specific mortality at a median of 10 years following randomisation. A monograph covering these findings is expected to be published in the NIHR Journals Library in July 2017. Findings from longer term follow-up will be published at a later stage.<\/p> <\/p> <\/p> <\/p> <\/strong><\/p> <\/p> <\/strong><\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
, "dateOfAnswer" : {"_value" : "2015-09-16", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2015-09-16T15:17:51.32Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2015-09-11", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Prostate Cancer"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, when he expects the final results of the National Institute for Health Research's ProtecT trials for prostate cancer testing to be published; and if he will make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1409", "label" : {"_value" : "Biography information for Mr Gregory Campbell"}
}
, "tablingMemberConstituency" : {"_value" : "East Londonderry"}
, "tablingMemberPrinted" : [{"_value" : "Mr Gregory Campbell"}
], "uin" : "9996"}
, {"_about" : "http://data.parliament.uk/resources/418456", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/418456/answer", "answerText" : {"_value" : " The Department's National Institute for Health Research (NIHR) welcomes funding applications for research into any aspect of human health, including muscular dystrophies. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money and scientific quality.<\/p> <\/p> <\/p> <\/p> Research on novel approaches to treating neuromuscular disease including Duchenne muscular dystrophy is being carried out by the NIHR Biomedical Research Centre at Great Ormond Street Hospital for Children NHS Trust and the University College London Institute of Child Health.<\/p> <\/p> <\/p> <\/p> The NIHR Health Technology Assessment programme is currently seeking to commission research on the effectiveness and cost-effectiveness of mechanical insufflation-exsufflation devices when compared to other methods of sputum clearance commonly used in children and young people with neuromuscular disease.<\/p> <\/p> <\/p> <\/p> <\/p> <\/p> <\/strong><\/p> <\/p> <\/strong><\/p> <\/p> <\/strong><\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
, "dateOfAnswer" : {"_value" : "2015-09-16", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2015-09-16T15:27:44.917Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2015-09-11", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Muscular Dystrophy"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, what steps he is taking to promote research into muscular dystrophy conditions.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1409", "label" : {"_value" : "Biography information for Mr Gregory Campbell"}
}
, "tablingMemberConstituency" : {"_value" : "East Londonderry"}
, "tablingMemberPrinted" : [{"_value" : "Mr Gregory Campbell"}
], "uin" : "9997"}
, {"_about" : "http://data.parliament.uk/resources/418458", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/418458/answer", "answerText" : {"_value" : " The Government fully appreciates the impact that sight loss can have on a person\u2019s life and the importance of information being available for those newly diagnosed with sight loss, including signposting patients to appropriate support and rehabilitation services.<\/p> <\/p> <\/p> <\/p> Eye clinics and their staffing, including eye clinic liaison officers, are commissioned and funded by individual clinical commissioning groups on the basis of local assessments of need.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/1201", "label" : {"_value" : "Biography information for Alistair Burt"}
}
, "answeringMemberConstituency" : {"_value" : "North East Bedfordshire"}
, "answeringMemberPrinted" : {"_value" : "Alistair Burt"}
, "dateOfAnswer" : {"_value" : "2015-09-16", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "9977"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2015-09-16T12:01:58.77Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2015-09-11", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Ophthalmic Services"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, what recent assessment he has made of the effect of eye clinic liaison officers on improving patient health and social care; and what progress he has made on increasing the provision of such officers.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/253", "label" : {"_value" : "Biography information for Mr Laurence Robertson"}
}
, "tablingMemberConstituency" : {"_value" : "Tewkesbury"}
, "tablingMemberPrinted" : [{"_value" : "Mr Laurence Robertson"}
], "uin" : "9980"}
, {"_about" : "http://data.parliament.uk/resources/418459", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/418459/answer", "answerText" : {"_value" : " The Government fully appreciates the impact that sight loss can have on a person\u2019s life and the importance of information being available for those newly diagnosed with sight loss, including signposting patients to appropriate support and rehabilitation services.<\/p> <\/p> <\/p> <\/p> Eye clinics and their staffing, including eye clinic liaison officers, are commissioned and funded by individual clinical commissioning groups on the basis of local assessments of need.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/1201", "label" : {"_value" : "Biography information for Alistair Burt"}
}
, "answeringMemberConstituency" : {"_value" : "North East Bedfordshire"}
, "answeringMemberPrinted" : {"_value" : "Alistair Burt"}
, "dateOfAnswer" : {"_value" : "2015-09-16", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "9980"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2015-09-16T12:01:58.707Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2015-09-11", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Ophthalmic Services"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, what funding his Department provides for eye clinic liaison officers.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/253", "label" : {"_value" : "Biography information for Mr Laurence Robertson"}
}
, "tablingMemberConstituency" : {"_value" : "Tewkesbury"}
, "tablingMemberPrinted" : [{"_value" : "Mr Laurence Robertson"}
], "uin" : "9977"}
, {"_about" : "http://data.parliament.uk/resources/418460", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/418460/answer", "answerText" : {"_value" : " Evidence based advice on the care of women with multiple pregnancies is set out in the National Institute for Health and Care Excellence (NICE ) Clinical Guidelines \u2018Multiple Pregnancies \u2013 The management of twin and triplet pregnancies in the antenatal period\u2019. In line with these guidelines, we would expect clinical care for women with twin and triplet pregnancies to be provided by a nominated multidisciplinary team consisting of a core team, including named specialist obstetricians, who have experience and knowledge of managing twin and triplet pregnancies. The Department has not undertaken an assessment of the effectiveness of the implementation of the NICE guidelines.<\/p> <\/p> <\/p> <\/p> Local maternity care providers are responsible for determining how best to deliver services for women with multiple pregnancies in their area. In doing so we would expect them to give due regard to NICE guidelines.<\/p> <\/p> <\/p> <\/p> NHS England has asked Baroness Julia Cumberlege to lead a major review of maternity services to modernise care for women and babies across the country, as first set out in NHS England\u2019s Five Year Forward View. The independent review group is assessing current maternity care provision, considering the evidence on different models of care and will make recommendations on how services should be developed to meet the changing needs of women and babies. The group met for the first time on 23 April and it plans to report by the end of the year. More information is available at:<\/p> <\/p> <\/p> <\/p> http://www.england.nhs.uk/2015/05/29/julia-cumberlege-2/<\/a><\/p> <\/p> <\/strong><\/p> <\/p> <\/strong><\/p> <\/p> <\/strong><\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/3988", "label" : {"_value" : "Biography information for Ben Gummer"}
}
, "answeringMemberConstituency" : {"_value" : "Ipswich"}
, "answeringMemberPrinted" : {"_value" : "Ben Gummer"}
, "dateOfAnswer" : {"_value" : "2015-09-16", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2015-09-16T15:29:19.46Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2015-09-11", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Multiple Births"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, what recent assessment he has made of the (a) extent and (b) effectiveness of sharing of best practice of implementation of guidance on multiple pregnancies between NHS hospital trusts.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/253", "label" : {"_value" : "Biography information for Mr Laurence Robertson"}
}
, "tablingMemberConstituency" : {"_value" : "Tewkesbury"}
, "tablingMemberPrinted" : [{"_value" : "Mr Laurence Robertson"}
], "uin" : "9978"}
, {"_about" : "http://data.parliament.uk/resources/418463", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/418463/answer", "answerText" : {"_value" : " NHS England works in partnership with local commissioners and providers to ensure people with long-term conditions, such as hidradenitis suppurativa (HS), are supported to live healthily and independently and are empowered to take better control over the care they receive.<\/p> <\/p> <\/p> <\/p> The majority of patients with HS can be managed through routine access to primary and secondary care, including dermatology clinics, which is responsibility of the local National Health Service commissioners. Treatment and management of the condition involves antibiotics, antiseptic washes and immunosuppressive treatments such as steroids or ciclosporin, which a general practitioner may prescribe.<\/p> <\/p> <\/p> <\/p> For those patients with the more serious forms of HS, referral to a specialised dermatology service may be appropriate. NHS England commissions services for people with rare and complex skin conditions, including HS, and has set out what providers must have in place in order to offer specialist dermatology care. This supports equity of access to a high quality service for patients wherever they live. These services may provide more intensive therapies with the involvement of a range of health and care professionals, subject to a patient\u2019s needs. More information can be found by viewing the specialised dermatology service specification at the following link:<\/p> <\/p> <\/p> <\/p>